Trial · NCT02745145
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Absolute Forced Vital Capacity (FVC) at Week 52 | Placebo | -130 | Standard Deviation 56.6 | milliliters | |
| Change From Baseline in Absolute Forced Vital Capacity (FVC) at Week 52 | Abituzumab 1500 mg | -50 | Standard Deviation NA | milliliters | |
| Change From Baseline in Dyspnea as Measured by the Mahler's Transition Dyspnea Index (TDI) at Week 52 | Placebo | 3 | Standard Deviation NA | Score on a scale | |
| Change From Baseline in Dyspnea as Measured by the Mahler's Transition Dyspnea Index (TDI) at Week 52 | Abituzumab 1500 mg | 4 | Standard Deviation NA | Score on a scale | |
| Absolute Change From Baseline in St. George Respiratory Questionnaire (SGRQ) Total Score at Week 52 | Placebo | 6.4 | Standard Deviation NA | Scores on a scale | |
| Absolute Change From Baseline in St. George Respiratory Questionnaire (SGRQ) Total Score at Week 52 | Abituzumab 1500 mg | 1.4 | Standard Deviation NA | Scores on a scale | |
| Absolute Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 52 in Participants With Diffuse Cutaneous Skin Involvement at Baseline | Placebo | 0 | Standard Deviation NA | Scores on a scale | |
| Absolute Change From Baseline in Quantitative Lung Fibrosis (QLF) in the Region of Highest Baseline Severity at Week 52 | Placebo | 6.29 | Standard Deviation 2.638 | Scores on a scale | |
| Absolute Change From Baseline in Quantitative Lung Fibrosis (QLF) in the Region of Highest Baseline Severity at Week 52 | Abituzumab 1500 mg | -2.27 | Standard Deviation NA | Scores on a scale | |
| Overall Survival (OS) | Placebo | Number of deaths | 0 | Participants | |
| Overall Survival (OS) | Abituzumab 500 mg | Number of deaths | 1 | Participants | |
| Overall Survival (OS) | Abituzumab 1500 mg | Number of deaths | 0 | Participants | |
| Overall Survival (OS) | Placebo | Number for censored | 10 | Participants | |
| Overall Survival (OS) | Abituzumab 500 mg | Number for censored | 4 | Participants | |
| Overall Survival (OS) | Abituzumab 1500 mg | Number for censored | 9 | Participants | |
| Number of Participants With Clinically Meaningful Progression of Systemic Sclerosis (SSc) by Meeting Criterion 1 (Interstitial Lung Disease [ILD]) | Placebo | 0 | Participants | ||
| Number of Participants With Clinically Meaningful Progression of Systemic Sclerosis (SSc) by Meeting Criterion 1 (Interstitial Lung Disease [ILD]) | Abituzumab 500 mg | 0 | Participants | ||
| Number of Participants With Clinically Meaningful Progression of Systemic Sclerosis (SSc) by Meeting Criterion 1 (Interstitial Lung Disease [ILD]) | Abituzumab 1500 mg | 2 | Participants | ||
| Number of Participants With Clinically Meaningful Progression of Systemic Sclerosis (SSc) by Meeting Criterion 2 (SSc Progression Other Than ILD) | Placebo | 0 | Participants | ||
| Number of Participants With Clinically Meaningful Progression of Systemic Sclerosis (SSc) by Meeting Criterion 2 (SSc Progression Other Than ILD) | Abituzumab 500 mg | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02745145/results